Genmab Files Comprehensive 2025 Annual Report, Details Merus Acquisition, $5.5B Debt, and 2026 Outlook
GMAB sits 78% above its 52-week low of $17.235.
Summary
Genmab A/S filed its comprehensive 2025 annual report (Form 20-F), detailing the $8.017 billion acquisition of Merus, the associated $5.5 billion in new debt, and providing 2026 financial guidance. The report also updates on significant pipeline progress and ongoing legal challenges.
Key Events · Corporate Governance and Compliance · GMAB
-
2025 Financial Performance
Reported revenue of $3.72 billion for 2025, a 19% increase from 2024, with an operating profit of $1.065 billion. Royalty revenue, primarily from DARZALEX and Kesimpta, increased by 23% to $3.102 billion.
-
2026 Financial Guidance Issued
Provided 2026 revenue guidance in the range of $4.1 - $4.4 billion and operating profit guidance between $0.9 - $1.4 billion. Operating expenses are projected to increase to $2.7 - $2.9 billion due to investments in late-stage programs and launch readiness.
-
Merus Acquisition and Debt Financing
Completed the $8.017 billion acquisition of Merus in December 2025, significantly expanding its proprietary pipeline. The acquisition was financed by incurring $5.5 billion in new senior secured and unsecured debt.
-
Key Pipeline Advancements
Detailed progress on proprietary and partnered products, including EPKINLY's full FDA approval in combination with R2 for relapsed/refractory FL (November 2025) and Tivdak's approvals in Europe and Japan (March 2025). Rina-S advanced into Phase 3 development for PSOC and endometrial cancer, and petosemtamab received two Breakthrough Therapy Designations from the FDA.
Analysis · GMAB · Life Sciences
Genmab's 2025 annual report provides a comprehensive overview of its financial performance, strategic initiatives, and pipeline advancements. The most significant disclosures include the full financial results for 2025, the substantial acquisition of Merus and its associated financing, and forward-looking guidance for 2026. The report also highlights ongoing legal challenges that could impact future operations. The acquisition of Merus and the related debt represent a major strategic move to expand the company's proprietary pipeline and diversify revenue streams, while the legal proceedings introduce material risks that investors should monitor.
At the time of this filing, GMAB was trading at $30.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2B. The 52-week trading range was $17.24 to $35.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.